류마티스관절염 치료지침 업데이트
Treatment Guidelines for Rheumatoid Arthritis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease with synovitis and extra-articular systemic involvement. Chronic RA treatment is challenging and represents a major health burden worldwide. Recent insights regarding RA pathogenesis have led to novel therapeutic agents, especially biologics. Furthermore, accumulating experience and new clinical studies have helped to inform updated recommendations for treatment of RA. Recently, treatment guidelines from the American College of Rheumatology were released. Here, we review these guidelines and their application to daily practice.
Abstract
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease with synovitis and extra-articular systemic involvement. Chronic RA treatment is challenging and represents a major health burden worldwide. Recent insights regarding RA pathogenesis have led to novel therapeutic agents, especially biologics. Furthermore, accumulating experience and new clinical studies have helped to inform updated recommendations for treatment of RA. Recently, treatment guidelines from the American College of Rheumatology were released. Here, we review these guidelines and their application to daily practice.
참고문헌 (10)
- McInnes IB, "The pathogenesis of rheumatoid arthritis", N Engl J Med, 365, pp.2205~2219 (2011)
- van Vollenhoven R, "Treat-to-target in rheumatoid arthritis-are we there yet?", Nat Rev Rheumatol, 15, pp.180~186 (2019)
- Monaco C, "Anti-TNF therapy : past, present and future", Int Immunol, 27, pp.55~62 (2015)
- Lau CS, "2018 update of the APLAR recommendations for treatment of rheumatoid arthritis", Int J Rheum Dis, 22, pp.357~375 (2019)
- Fraenkel L, "2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Care Res (Hoboken), 73, pp.924~939 (2021)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update", Ann Rheum Dis, 79, pp.685~699 (2020)
- Young Ho Lee, "Comparison of Disease Activity Score-28 Based on Erythrocyte Sedimentation Rate and C-reactive Protein Level in Rheumatoid Arthritis", 대한류마티스학회지, 25(1), pp.1~2 (2018), 대한류마티스학회[DOI]
- Ytterberg SR, "Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis", N Engl J Med, 386, pp.316~326 (2022)
- Kremer JM, "Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs : 5-year results from a United States-based rheumatoid arthritis registry", ACR Open Rheumatol, 3, pp.173~184 (2021)
- Singh JA, "2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Care Res (Hoboken), 68, pp.1~25 (2016)